
Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy
Keywords: FDA; Food and Drug Administration; HAART; highly active antiretroviral therapy; NNRTIs; non-nucleoside reverse transcriptase inhibitors; NRTIs; nucleoside reverse transcriptase inhibitors; OSHA; Occupational Health and Safety Administration; PUI; personal